Report of Foreign Issuer (6-k)
August 14 2019 - 8:01AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the month of: August 2019
|
Commission File Number: 001-35776
|
ACASTI PHARMA INC.
(Name of Registrant)
545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐
No ☒
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): N/A
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
ACASTI PHARMA INC.
|
Date: August 14, 2019
|
By:
|
/s/ Jan D’Alvise
|
|
|
Name: Jan D’Alvise
Title: Chief Executive Officer
|
EXHIBIT INDEX
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Sep 2023 to Sep 2024